Valencia Technologies

Valencia Technologies is a private, commercial-stage medical device company pioneering a novel, minimally invasive neuromodulation therapy for Urge Urinary Incontinence (UUI). Its FDA-approved eCoin® device is a leadless, self-contained neurostimulator implanted near the ankle, offering a drug-free, long-term treatment option that eliminates the need for leads, patient-managed remotes, or recharging. The company is led by an experienced team with a strong track record in neuromodulation and medical device commercialization, and it is currently positioned for accelerated commercial growth following a recent strategic investment and leadership appointment.

Leadless, implantable tibial nerve neurostimulation platform for minimally invasive, long-term neuromodulation therapy.

Valencia competes in the advanced OAB/UUI treatment market against pharmaceutical giants (e.g., Astellas, Pfizer), botulinum toxin (AbbVie/Allergan), and established neuromodulation devices like Medtronic's InterStim and Axonics' sacral neuromodulation system. eCoin's key differentiator is its minimally invasive, leadless, and non-rechargeable design.